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Abstract
The ability to control cellular functions can bring about many developments in basic biological research and its applications.
The presence of multiple signals, internal as well as externally imposed, introduces several challenges for controlling cellular
functions. Additionally the lack of clear understanding of the cellular signaling network limits our ability to infer the
responses to a number of signals. This work investigates the control of Kaposi’s sarcoma-associated herpesvirus reactivation
upon treatment with a combination of multiple signals. We utilize mathematical model-based as well as experiment-based
approaches to achieve the desired goals of maximizing virus reactivation. The results show that appropriately selected
control signals can induce virus lytic gene expression about ten folds higher than a single drug; these results were validated
by comparing the results of the two approaches, and experimentally using multiple assays. Additionally, we have
quantitatively analyzed potential interactions between the used combinations of drugs. Some of these interactions were
consistent with existing literature, and new interactions emerged and warrant further studies. The work presents a general
method that can be used to quantitatively and systematically study multi-signal induced responses. It enables optimization
of combinations to achieve desired responses. It also allows identifying critical nodes mediating the multi-signal induced
responses. The concept and the approach used in this work will be directly applicable to other diseases such as AIDS and
cancer.
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Introduction
There is an increasing interest in utilizing and applying systems
biological approaches to study a wide range of problems in
biology. In this work, we apply different systems biological
approaches to investigate the effects of multiple signals on cellular
signaling processes with the goals of understanding and controlling
these processes. As a model systems, we use the reactivation of
Kaposi’s Sarcoma-associated herpesvirus (KSHV) to investigate
the effects of several drugs on a quantifiable process, virus
reactivation. KSHV, also known as human herpesvirus-8 (HHV-
8), is a member of the herpesvirus family, which includes simplex
viruses, Epstein-Barr virus (EBV) and cytomegalovirus [1,2]. A
significant amount of malignancies are associated with herpesvirus
infection. Epstein-Barr virus (EBV) is associated with non-
Hodgkins lymphomas and nasopharyngeal carcinoma (NPC).
Human herpesvirus-8/Kaposi’s sarcoma-associated herpesvirus
(HHV-8/KSHV) is the etiologic agent of Kaposi’s sarcoma (KS),
the most frequently occurring malignancy in AIDS patients.
Additionally, KSHV establishes long-term latent infection in
lymphocytes and is associated with primary effusion lymphoma
and lymphoproliferative diseases [2].
Herpesviruses have two distinct phases in their life cycle: latency
and lytic replication. Latency is one strategy for viruses to achieve
life-long persistent infection. During latency, the viral genome is
replicated by cellular DNA polymerase and only a few gene
products are expressed at low levels. A reactivation process causes
the virus to enter the lytic replication state from latency and upon
replication of the viral genome by a viral DNA polymerase, viral
progeny are produced, frequently resulting in cell death. Virus
reactivation is controlled by a cellular signaling process in which
cellular signals are amplified and can be measured with markers
such as Green Fluorescent Protein (GFP) or luciferase. In earlier
work, we identified RTA (replication and transcription activator)
of KSHV, an immediate-early gene, as the switch in the
reactivation process [3–5]. In latently-infected cells, the expression
of RTA is necessary and sufficient to disrupt KSHV latency and
trigger the complete lytic replication process [3]. RTA functions as
a transcription factor which activates, in addition to its own,
multiple downstream genes including the early viral transcript
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viral lytic cascade. PAN is directly activated by RTA and is the
most abundant viral transcript in the lytic cycle [3,6–8].
Reactivation, the switch from latency to lytic replication, is an
important process for KSHV pathogenesis and a target for the
development of therapeutic strategies for the associated tumors.
Investigation of the multi-drug regulated reactivation process
provides important information for the associated cancer treat-
ment. It should be therapeutically advantageous to intentionally
activate the viral lytic cycle in tumor cells in the presence of an
anti-herpesviral drug, such as ganciclovir [9,10]. The expression of
viral thymidine kinase (vTK) and phosphotransferase (vPT), both
viral early lytic genes, will allow ganciclovir to be phosphorylated
in infected cells, leading to inhibition of DNA replication. In
addition, metabolized ganciclovir can cause additional ‘‘bystand-
er’’ killing effects [11,12] that may result in lysis of neighboring
tumor cells. Furthermore, strong immune responses to a large
amount of lytic antigens may contribute to the destruction of
tumor lesions.
Maximal induction of virus replication is necessary for an
effective therapeutic approach. Several studies have looked at
inducing KSHV reactivation with a single drug [13–16]. While a
single drug can induce KSHV reactivation, an effective agent for
clinical applications is yet to be identified. Achieving high rates of
lytic-cycle reactivation of KSHV may require the concurrent
activation of several signal transduction pathways within the cell.
However, the use of multiple drugs brings about several challenges
such as the experimental complexity associated with testing several
drugs with various concentrations. The sequential addition of a
different drug to an optimal combination of drugs need not
provide optimal results due to the complexity of the signaling
network. Additionally, the use of multiple signals may not induce
an increase in viral lytic replication as activation of some non-
primary targets can be cause unexpected results in the presence of
combinations of drugs, potentially leading to blocking of virus
reactivation. Furthermore, multiple signals can cause deregulation
of multiple cellular processes leading to cell stress and ultimately
cell death.
Here, we utilize different approaches to study the problem of
multi-signal induced KSHV reactivation. First, we utilized
mathematical modeling and learning tools to enable systematic
and effective selection of combinations of drugs that can result in
high reactivation. This approach is based on using input-output
data obtained by testing a relatively small number of signal
combinations to create a mathematical model that can predict the
responses to the complete space of combinations of considered
signals and their respective concentrations. The model, in turn, was
used for further analysis of the system and to select combinations
that can control the cellular responses in a desired manner. Second,
we utilized a stochastic search algorithm to drive a set of
experimental trials with the goal of identifying combinations of
signals that can yield high reactivation. The results of both
approaches were compared and further experimental assays were
used to validate the results. Third, we used a combination of linear
regression models and subset selection algorithms to identify key
factors influencing the multi-signal driven responses. We were able
to identify multiple drug interactions that play a dominant role in
the response. These interactions represent a subset of the possible
connections between the signaling targets.
Results
Five drugs were selected to be tested in combination (See
Materials and Methods). Each of the drugs reactivates KSHV with
varying degrees. With the utilization of the five drugs that function
indifferentyetpotentiallyconnectedsignalingprocesses(Figure1A),
KSHV reactivation can serve as an excellent model system
illustrating how multiple cellular signals are processed. The five
drugs are: Bortezomib, db-cAMP, Prostratin, Valproate, and
Dexamethasone. Bortezomib is a proteasome inhibitor that at least
in part reactivates KSHV by inhibiting NF-kB activity [13].
DibutyrylcAMP (db-cAMP) is a cell-permeable cAMP analog that
activates the PKA pathway [14]. Prostratin activates the PKC
pathway [13]. Valproate shares structure and mechanism similar-
ities with the histone deacetylase inhibitor butyrate [15]. Dexa-
methasone is a glucocorticoid regulating the activation of some
transcription factors and apoptosis-related genes [16,17].
In order to quantify the viral reactivation response, the RTA
binding site in the PAN promoter was identified [7] and a GFP
reporter system was constructed. The reporter system BC-3-G,
uses BC-3 cells (a primary effusion lymphoma cell line latently
infected with KSHV) where a GFP protein is expressed under the
control of a minimal lytic promoter of Polyadenylated Nuclear
RNA (PAN), the most abundant KSHV early lytic transcript
[4,8,18]. Therefore, the expression of GFP following the activation
of the PAN promoter served as a sensitive indicator of KSHV
reactivation. The specificity of the reporter has been demonstrated
in a previous study [19].
Measurement of virus reactivation was achieved using flow
cytometry where we measured the number of activated cells, i.e.,
GFP positive, and the total number of cells, i.e., the number of
dead and living cells. The reactivation rate (performance) of any
given combination was set to be the ratio of GFP positive cells to
the total number of cells including dead cells.
Modeling of mutli-signal induced KSHV reactivation
Investigation of the combinatorial effect of multiple participat-
ing pathways on reactivation can be achieved by treating the
latently-infected cells with related chemical agents. Single drug
dose curves for each chemical agent were obtained to determine
the range of effectiveness of each individual chemical agent
(Figure 1B). Based on the sensitive range of each individual agent
determined from the curves, we selected the ranges of the
concentrations to be used. Subsequently, the ranges were divided
into ten concentrations using two-fold dilutions and setting the
lowest concentration to zero (Table 1). The ten different
concentrations of each drug comprised an input space of 105
possible drug combinations in total. Testing this number of
combinations poses significant challenges (cost, labor, time, etc…).
The choice of 10 concentrations depends on the shape and
smoothness of the response and can be increased for finer
sampling of the system response. However, the increase will lead to
an increase in the number of tests.
Using a uniform probability distribution over the set of all
combinations of concentrations of five drugs, we randomly
selected 600 different combinations to be experimentally tested.
Six sets of experiments were conducted. In each set, 100 data
points along with a positive control, a single drug (TPA) known to
reactivate the virus [20,21], were evaluated using the GFP reporter
system. The latently infected BC-3-G cells were treated with the
combinations for one hour, after which the drugs were washed
out, and measurements were taken 16 hours later to allow enough
time for GFP synthesis and assembly upon reactivation.
The inputs (drug combinations) and their corresponding
measured outputs (reactivation rates) were used to generate a
mathematical model, KSHV reactivation model. The predictive
reactivation model approximates the KSHV reactivation rate as
induced by a combination of drugs within the specified range of
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predict reactivation rates in response to all combinations of the five
chemical agents. The combinations are not limited to the 600
tested combinations and include all combinations of the lower
order mixtures, i.e., two, three, and four-drug combinations. The
use of this relatively small number of combinations is facilitated by
the assumption that the response function to these five drugs is
reasonably smooth. If the response function is not very smooth
then it would require testing of additional combinations to
improve the accuracy and prediction power of the model.
Several methods can be used to generate a mathematical model.
We utilize neural networks, linear regression [22,23], and partial
least squares regression [24]. Artificial neural networks are
biologically inspired adaptive information processing systems.
Artificial neural networks have been successfully applied to a wide
range of problems in various disciplines including biological,
medical, engineering, and financial [25,26]. The combination of
linear regression with partial least squares or all subset regression
provided the ability to reduce the dimensionality of the problem
and provides insight into which variables have the most influence
on the observed responses.
We trained a multi-layered perceptron with the data and
obtained a representative predictive model (see the Material and
Methods section). The model gave a correlation coefficient of more
than 95% between the calculated and experimental data of the
training set (Figure 2A). This indicates that the model has a
reasonable prediction power butrequires generalization. Therefore,
the model was tested with an independently and randomly selected
data set of 48 different combinations experimentally tested several
months after the 600 points. The model was able to predict the
corresponding reactivation rates with a correlation coefficient of
82%, a good fit considering the variability of cell responses due to
varying cell conditions at different measurement times (Figure 2B).
Model-based optimization of KSHV reactivation
The predictive model generated provides the ability to
determine combinations that can lead to high reactivation rates
as predicted by the model. The simulated reactivation rates of all
105 combinations were enumerated. A simple sorting algorithm
was used to rank the combinations in order of simulated
reactivation rates. It is important to note that while a single best
performing combination can be selected based on enumeration of
all performances, the relevance of this best performing combina-
tion is not high due to measurement noise and modeling errors.
Therefore, one is interested in looking at the distribution of top
performing combinations. The top ranking 50 combinations were
determined (Figure 3A). The distributions of individual concen-
trations within this group of points shows that lower to middle
concentrations of Bortezomib are predominant. The distribution
of concentrations of the other four drugs indicates that medium to
high concentrations are predominant. The distribution of the
performances within the top performing points indicates that the
variation is within 3% of the maximum.
An alternate approach to determine the top performing
combinations is to utilize a search algorithm, deterministic or
stochastic. Examples include gradient descent algorithms [27],
genetic algorithms [28], the cross entropy method (CE) [29–31], as
well as other stochastic search and combinatorial optimization
algorithms. While a simple sorting algorithm suffices to sort all the
performances, we apply a stochastic search algorithm here to
search for optimal combinations based on the model to mimic
similar experiments that we performed. This enables us to
compare the outcomes of the two search experiments and to
assess the possibility of running such algorithms to drive a set of
experiments.
The cross entropy algorithm was implemented in silico using the
KSHV predictive reactivation model (see Materials and Methods).
The simulated CE optimization showed that generally after about
14 iterations, the individual drug concentrations converged to 0 or
1.25 nM for Bortezomib, 4 mM or 8 mM for db-cAMP, 40 uM
or 80 uM for Prostratin, 6 mM for Valproate, and 100 nM
or 200 nM for Dexamethasone, to achieve consistently high
reactivation (Figure 3A). The approach for optimizing combina-
tions through the simple selection of the maximum possible dose of
each drug does not result in a better reactivation rate than the
optimized combination. The reactivation rate with the maximum
Figure 1. Single-drug effects of KSHV reactivation and related
cellular signaling. (A) Shown are the five drugs that are used in the
drug combinations and the mechanisms by which they induce KSHV
reactivation. The diagram also illustrates the known crosstalk among
t h e s ef i v ed r u g s .? : Synergistic effect; \ : Inhibitory effect.
Representative known interactions among different molecules: a.
Proteasome inhibitor prevents the activation of NF-kB [43,44]. b. PKC
activates NF-kB in T and B lymphocytes [45,46]. c. NF-kB inhibits
herpesvirus reactivation in vitro and in vivo [13,47]. d. Glucocorticoids
such as Dexamethasone inhibit NF-kB activity through induction of IkB
[48,49]. e. Dexamethasone and cAMP may synergistically regulate the
expression of a subset of genes in lymphocytes [40]. f. PKA pathway and
PKC pathway can synergize [50] or antagonize [51] each other in
different circumstances. (B) Shown are the KSHV reactivation rates upon
treatment with the five drugs individually (Blue: Bortezomib, Red: db-
cAMP, Green: Prostratin, Purple: Valproate, Cyan: Dexamethasone). The
nine concentrations used are nine two-fold dilutions of the following
maximum concentrations for the drugs Bortezomib 320(nM), db-cAMP
8(mM), Prostratin 80(uM), Valproate 6(mM), Dexamethasone 400(nM).
The concentrations are also the nine concentrations (Conc. I) in Table 1.
doi:10.1371/journal.pone.0020998.g001
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is about 42% with the optimized combination.
Experiment-based optimization of KSHV reactivation
An alternate approach to optimizing drug combinations is the
use of a search algorithm implemented experimentally rather than
on a mathematical model. Recently, several examples of this
approach has emerged in biology [32–36]. This approach can
identify potent combinations and is useful in many situations
where one is only interested in knowing which combination
maximizes a pre-defined performance function.
The experimental cross entropy implementation proceeded in a
sequence of experimental iterations. Our results showed that after 12
to 14 iterations, the drug concentrations converged to the ranges
leading to consistently high reactivation rates (Figure 3B). The
concentration ranges were 0–5 nM for Bortezomib, 4–8 mM for db-
cAMP, 20–40 uM for Prostratin, 1.5–3 mM for Valproate, and a
wide range of 0–200 nM (centered around 100 nM) for Dexameth-
asone. We further narrowed down the drug concentration ranges
through another small set of iterations with drug concentrations more
densely distributed within the initially determined ranges (Table 1).
As expected, more consistently high reactivation rates were observed
with the progress of the CE iterations. The optimal drug
combinations obtained from the experimental CE method were
consistent with the results from the simulated CE method as well as
the direct enumeration (Figure 3A). This result experimentally
validated the feasibility of a model-based approach in characterizing
and optimizing multi-drug combinations.
Functional validation of selected combinations
Using two different approaches, we were able to identify a range
of concentrations for which high virus reactivation rates are
achievable. The results of the two approaches were consistent. To
further validate the findings, we conducted sets of experiments to
compare the performance of a selected combination from the
identified range to the performances of single drugs.
Table 1. Table of drug concentrations used in this study.
Drug Name Conc. No. 1 2 3 4 5 6 7 8 9 10
Bortezomib Conc. I (nM) 0 1.25 2.5 5 10 20 40 80 160 320
(C1) Conc. II (nM) 0 1.25 2.5 3.75 5
db-cAMP Conc. I (mM) 0 0.03 0.06 0.13 0.25 0.5 1 2 4 8
(C2) Conc. II (mM) 4 5 6 7 8
Prostratin Conc. I (uM) 0 0.31 0.63 1.25 2.5 5 10 20 40 80
(C3) Conc. II (uM) 20 25 30 35 40
Valproate Conc. I (mM) 0 0.02 0.05 0.09 0.19 0.38 0.75 1.5 3 6
(C4) Conc. II (mM) 1.5 2 2.5 3 3.5
Dexamethasone Conc. I (nM) 0 1.56 3.12 6.25 12.5 25 50 100 200 400
(C5) Conc. II (nM) 0 3 25 100 200
Conc. I indicates the concentration used for the model-based KSHV reactivation modeling and for the experiment-based optimization. Conc. II indicates the set of
refined concentrations used in the second part of the experiment-based optimization. These concentrations were used in Figures 1 and 3.
doi:10.1371/journal.pone.0020998.t001
Figure 2. Predictive modeling of reactivation rates. (A) Shown is the correlation between the measured reactivation (x-axis) and the predicted
reactivation (trained outputs) (y-axis) using 588 out of 600 total input-output points (see methods section - Neural network model). The circles
represent individual data points. The dotted diagonal line represents a perfect fit between the measured and predicted reactivation rates. (B) The
measured and predicted reactivation rates of 48 new randomly selected drug combinations. The x-axis shows the measured reactivation rates, and
the y-axis showed the predicted reactivation rates using the predictive reactivation model.
doi:10.1371/journal.pone.0020998.g002
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after the expression of KSHV RTA (ORF50). It is important for
initiating viral DNA replication in the lytic cycle, thus a good
marker for viral lytic replication. Western blot analysis of K8
showed that the selected drug combination can cause a much
higher induction of K8 than any single drug. The conclusion was
consistent 8 hours and 12 hours post treatment (Figure 4A).
Additionally, we looked at the effect of the selected drug
combination on the KSHV lytic transcripts RTA (ORF50) and
PAN. RTA plays a central role in regulating the switch from
latency to lytic replication in KSHV [3]. The activation of RTA
(ORF50) is the first event in KSHV reactivation. It encodes the
initiator of the viral lytic gene expression program. PAN
(polyadenylated nuclear RNA), is the most abundant transcript
made during the lytic cycle, and is directly induced by RTA [6].
Quantitative analysis of these two lytic transcripts shows results
similar to the western blot study of K8. Both lytic transcripts were
induced approximately ten folds higher using the selected
combination than the best concentration of any single drug. The
results were also consistent at two different time points (Figure 4B).
Our data shows that the combination treatment can potentially
accelerate the reactivation process. Furthermore, we tested the
virion production using Q-PCR upon treatment with a single drug
and the optimal combination. The results show that there is an
increase in virion production with the optimal combination over
any single drug (Figure 4C).
Examining drug interactions
The signaling network involves complex connections between
various molecules that can be perturbed through a large number
of external signals. The signals can cause inhibition of certain
molecules/pathways and stimulation of others. The interactions
amongst these molecules or pathways are very complex and very
hard to predict. Alternately, looking at interactions between the
input signals and the measured cellular outputs can shed some
light on the induced behaviors at the systems level. Particularly, we
can uncover some of the interactions of the signaling that are
involved in generating the responses upon stimulation with
multiple stimuli.
Based on the predictive reactivation model, we simulated the
interactions generated by the five drugs. The data represents a
complex multi-dimensional data set. While some mathematical
tools can be useful in reducing this complexity, one might be
interested in visually examining the behaviors represented by such
a large data set. To that end we created an interactive webpage
which displays the KSHV reactivation rates for varying concen-
trations of the considered drugs [37].
Our findings indicate that the dose dependent effect of the
individual drugs on reactivation greatly depended on the amounts
of the other drugs within the same treatment (Figure 5, webpage
on accompanying CD). The results clearly indicate that drugs can
interact to produce higher levels of cellular activity. However this
improvement in reactivation is dependent on the concentrations of
the drugs and needs to be optimized. The KSHV reactivation rate
in the absence of drugs Valproate and Dexamethasone are less
than the corresponding rates when these two drugs are present at
certain concentrations (Figure 5). The non-optimized addition of
drugs to the system might not result in a noticeable improvement.
In addition, the presence of appropriate doses of the drugs
Valproate and Dexamethasone results in an increase of the
effective range (the range for which high reactivation rates can be
achieved) of drugs Bortezomib, db-cAMP, Prostratin. This
provides the ability to use the drugs with lower concentrations
while maintaining high reactivation rates.
The addition of low concentrations of Bortezomib to combina-
tions of db-cAMP and Prostratin does not result in a significant
Figure 3. Characterization of the effect of drug combinations on KSHV reactivation. (A) Distribution of the concentrations of the five
drugs in the 50 drug combinations that lead to the highest KSHV reactivation rates simulated by the predictive reactivation model (blue bars). The
drug concentration ranges in the optimal drug concentrations generated by the experiment-based cross entropy procedure are shaded in red. The
bottom right figure shows a histogram of the reactivation rate of the top performing 50 samples. (B) Representative KSHV reactivation outputs for
five-drug combinations. The results of the 1st (top graph) and 12th (middle graph) iterations in the first set of optimization iterations, and the 3rd
(bottom graph) iteration in the second set of optimization iterations with smaller concentration ranges are shown. The x-axis represents the different
drug combinations used in each iteration; the y-axis shows relative percentage of GFP-positive cells in the total cell population. The highest
percentage of GFP-positive cells in individual iterations is set as 1.
doi:10.1371/journal.pone.0020998.g003
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result in a significant decrease in performance. Examining the
effect of only adding Valproate to combinations of Bortezomib,
db-cAMP, and Prostratin, we notice an increase in performance,
indicating that Valproate interacts positively with the three-drug
combinations to improve the reactivation. The sole addition of
Dexamethasone to combinations of Bortezomib, db-cAMP, and
Prostratin results in a smaller increase in performance. The
increase becomes less when high concentrations of Bortezomib are
used.
The above results reflect visual analysis of the responses, in the
sequel, we seek to quantitatively analyze these interactions to
determine the most significant ones. Such can be achieved using
mathematical modeling similar to what is used for optimization.
While a drawback of neural networks models is that they are
black-box models and do not shed light onto how the different
inputs are processed to produce the outputs, other modeling
techniques can help in this regard. We fitted a linear regression
model to represent the relationship between the drugs and the
reactivation (see methods section). The model utilizes 31 variables
(regressors) that represent drug concentrations as well as
interaction terms between the drugs.
The correlation coefficient between the experimental data and
predicted data based on the linear model was 85%, the correlation
coefficient for the additional 48 points was 83%. The model
provides an insight into which factors play the biggest role in the
response (Figure 6A). In agreement with the observations in the
single dose-response curves and the neural network model,
Prostratin and db-cAMP strongly influence virus reactivation.
Additionally, there are other two and three-drug interactions that
influence the response. Given this large number of model
variables, we sought to find the key variables that affect the
response. A partial least squares regression shows that around 10
components are sufficient to describe the variance in the output
data (Figure 6B). The components of partial least squares model
would be hard to interpret given the large number of variables.
Instead, we pursue a subset selection algorithm based on all the
Figure 4. Experimental validation of results. The figure shows the experimental validation results of the optimal drug combination for KSHV
reactivation determined via the cross entropy algorithm. (A) Western blots showing KSHV lytic protein K8 expression 8 hr or 12 hr after drug
treatment. The results were quantified as indicated in the material and methods section. (B) RT-Q-PCR showing the level of KSHV lytic transcripts
ORF50 and PAN 4 hr or 8 hr after drug treatment. (C) Q-PCR of virion DNA copy-numbers measured 48 hours after treatment.
doi:10.1371/journal.pone.0020998.g004
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models of 1,2,3,...,31 variables. In total, the algorithm provides
the best 31 models out of 231{1 possible models.
The residual sum of squares of the best models shows that there is
no significant reduction in the residual sum of squares for models
with more than 10 variables (95% reduction in the residual sum of
squares). This indicates that 10 variables are sufficient to generate a
model with comparable prediction and error to the 31-variable
model (Figure 6C). The 10 variables of the best 10-variable model
include theconcentrationsofthefive drugsand productsoftwo,and
three-drug concentration (Figure 6D). This shows that the response
is not only influenced by the individual drugs, but also by two and
three-drug interactions. Most notably, there is strong negative
interaction between Prostratin and Bortezomib, and strong positive
interactions between db-cAMP and Prostratin, db-cAMP and
Dexamethasone. A three-drug negative interaction between db-
cAMP,Prostratin,andDexamethasone isalso present.Examination
of models of 12 and 15 regressors shows that other three and four-
drug interactions are present such as Bortezomib–Prostratin–
Valproate, Bortezomib–db-cAMP–Prostratin, db-cAMP–Prostra-
tin–Valproate, Bortezomib–db-cAMP–Prostratin–Valproate, and
Bortezomib–db-cAMP–Prostratin–Dexamethasone.
Evaluation of effective subsets of combinations
Testing a system with five drugs provides advantages over studying
mixtures of a smaller set of drugs. A system level study of combinations
of multiple drugs enables fast and effective selection of a smaller subset
of drugs that is most potent. Although a set of five drugs was used in
this study, it is sometimes desirable to use a smaller number of drugs
that can interact in a desirable way. We computed the maximum
predicted reactivation rate for all possible mixtures of two, three, four,
a n df i v ed r u g s ,a sw e l la sf o rs i n g l ed r u g s( F i g u r e7 A ) .T h ef i g u r es h o w s
there are significant differences between the maximum achievable
reactivation rates using two, three and four drugs.
For two-drug mixtures, there is over a six-fold difference between
best and worst two-drug combinations. A mixture of Bortezomib and
Dexamethasone or Valproate and Dexamethasone perform poorly
even compared to a single drug. In contrast, a combination of db-
cAMP and Prostratin have a reactivation rate higher than the sum of
the individual reactivation rates. Prostratin and Valproate exhibit a
similar behavior. Thisis consistent with our findings of strong positive
interaction between Prostratin and Valproate. A mixture of
Bortezomib and Prostratin does not improve on the best reactivation
rate of Prostratin, suggesting negative or no interaction between the
two drugs. This is also consistent with the findings presented above.
For three-drug combinations, the best combination is more than
twice as effective as the worst mixtures. Furthermore, the best
three-drug mixture is about 130% more effective than the best
two-drug mixture. Four and five-drug mixture are slightly more
effective than the best three-drug mixture. The four-drug mixtures
generally perform better than than the three-drug mixtures.
Without a study of the combinations of five drugs, evaluating the
reactivation ratesforcombinationsoftwodrugsrequiresconducting
10 experiments individually to determine the maximum reactiva-
tion rate of the 10 possible two-drug combinations out of a set of
possible five drugs. Selection of three or four-drug combinations
requires similar experiments. Therefore, the combinations of the
systems approach, computational tools, and experimental design
enabled efficient multi-signal control of cellular/viral processes.
Discussion
Our results indicate that the use of combinations of drugs can
have a substantial effect on virus reactivation. In particular,
multiple drugs can interact and induce higher levels of virus
reactivation. However, the combination needs to be judiciously
selected out of a large number of drug concentration combina-
tions. The use of an improperly selected combination can have a
drastic effect on the cellular response and on virus reactivation.
The low reactivation rates of combinations imply either the
ineffectiveness of these combinations in reactivating the virus or
the high toxicity of these combinations. The biological relevance of
our results was supported by multiple experimental assays that
directly measured viral lytic replication products, and demon-
strated a synergistic reactivation by a proper drug combination,
much higher than by any individual drug, a pattern very consistent
with what was obtained in the fluorescent reporter system. The
measurement of virion production 48 hours post treatment also
confirms our findings and provides additional proof of the validity
of our approach. The work presented here, builds upon our recent
work in which the approaches used here were introduced to
address another problem of multiple signal response quantification
and analysis and were applied to study the differential response of
Figure 5. Multi-drug response maps of KSHV reactivation.
Figure showing plots of the KSHV reactivation rates as a function of
drugs db-cAMP and Prostratin, for various concentrations of drug
Bortezomib. The colors are solely a function of the reactivation levels in
each panel. (A) Drugs Valproate and Dexamethasone are fixed at zero.
(B) Drugs Valproate and Dexamethasone are fixed at 6 mM and
210.5 nM.
doi:10.1371/journal.pone.0020998.g005
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applications and illustrates the potency of such approaches.
Withthe developmentofgenomicsand proteomics,more and more
cellular components and their physical interactions are identified.
However, their dynamic functional interactions have not been studied
extensively or quantitatively. Systems biological approaches are
emerging with the aim of understanding these functional interactions.
In retrospect, a mathematical model-based approach provides means
for understanding system level behaviors exhibited by the interacting
cellular components in response to one or multiple stimuli.
Moreover, the emerging interest and need to develop
combination therapies and individualized medicine calls for
additional efforts in analyzing multi-signal induced cellular
responses. Studies should also involve examining multiple cellular
outputs or network signaling intermediates in response to multiple
cellular inputs. The approach used in this work is capable of
addressing such problems. Additionally, examining the kinetics of
cellular responses will allow for more dynamic control.
This study using KSHV reactivation as a model system to study
multi-signal response quantification, a general issue in cell biology.
The concept and the approach used in this work will be directly
applicable to other problems such as Epstein-Barr Virus (EBV)-
associated malignancies. Moreover, many cancers and HIV
associated malignancies can benefit from systematic approaches
to studying multi-signal induced responses.
Experiment-based versus model-based optimization
The selection of suitable drug combinations was achieved using two
different approaches. The experiment-based cross entropy implemen-
tation involved iterative testing of combinations in order to search for
best performing combinations. The algorithm showed reasonable
convergence. The advantages of experiment-based optimization are
apparent when the objective function is clearly defined and we are
interested in achieving that goal in a reasonably smaller number of
tests. Furthermore, when there is no interest in deducing more
information regarding the relationship between input signals and
output responses, an experiment-based optimization approach can
yield satisfactory results without added experimental overhead.
On the other hand, a model-based approach was also quite
effective in achieving the desired goals. The results were consistent
between the two different approaches emphasizing the power of
using various mathematical tools to study biological problems.
Generating a predictive model required testing a relatively small
number of drug combinations. As the combinations are tested over
a shorter period of time, the sensitivity of this approach to
variations in cell conditions is less prevalent than the experiment-
based approach. Another advantage of a model-based approach is
that it enables optimizing combinations based on a different
number of performance functions with varying sets of parameters
without additional experimental measurement. This allows
efficient analysis of multiple optimization questions and enables
Figure 6. Dimensionality reduction of the predictive reactivation model. (A) Plot of the regression coefficients of the different regressors
used in linear regression. (B) Plot of the percentage of variance explained as a function of the number of Partial Least Squares components used in
Partial Least Squares Regression. (C) Plot of the lowest residual sum of squares for models of 1,2,...,31 regressors. (D) Plot of the regressor
coefficients of the best model using 10 regressors. The regressors are shown as well.
doi:10.1371/journal.pone.0020998.g006
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tion of treatment based on an individual’s characteristics. The
model also can be used to study problems beyond the optimization
and control of cellular responses such as analyzing the relation-
ships between the various signals in view of the effects of these
signals on some measured the cellular outputs.
On network targets and interactions
The selected drugs target distinct parts within the signaling
network. Yet, there are significant interactions between the targets
ofthesedrugsthroughothermoleculeswithinthe signalingnetwork.
To illustrate this, we have summarized the interactions as predicted
by the neural network model and through the regression analysis
(Figure 7B). These interactions represent an abstracted set of
interactions that highlight the subset of the signaling network that is
most involved upon treatment with multiple drugsinthe tested cells.
The negative interaction between Bortezomib and Prostratin is
consistent with the observation based on the neural network
model. The positive interactions between db-cAMP and prostra-
tin, and valproate and Prostratin are also consistent with the
observations based on the neural network model. The reported
interactions indicate that PKC activates NF-kB in T and B
lymphocytes. It has been reported that NF-kB inhibits reactivation
both in vitro and in vivo (Figure 1A). In view of the more complex
Figure 7. Evaluation of combinatorial effects of drugs on reactivation and cellular signaling. (A) Plot of the maximum achievable
reactivation rates using combinations of two, three, four, and five drugs as predicted by the mathematical KSHV reactivation model. (B) A summary of
the predicted interactions between the applied drugs and their effects of these interactions on KSHV reactivation. ? : Synergistic effect; \: Inhibitory
effect.
doi:10.1371/journal.pone.0020998.g007
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remains unclear whether NF-kB is a potential target for the
interaction between Prostratin and Botezomib.
The comparison between known knowledge of the cellular
pathways targeted by the drugs and the potential interactions we
have obtained from the drug combination study can shed light on
the molecular mechanisms of reactivation regulation by cellular
factors. For example, some of our observations of the drug
interactions here are consistent with our knowledge about the
signaling pathways these drugs target. In view of the positive
interaction between db-cAMP and Dexamethasone, it is suggested
that Dexamethasone could potentiate PKA signaling and thereby
facilitate PKC signaling, possibly through the synergistic effect on
CRE-mediated gene expression, and CREB may be playing an
important role in the mediation of CRE-dependent transcription
[40,41]. A speculation of the phenomenon we observed in our
reactivation system is that at low PKA and PKC activity level, the
synergizing effect between Bortezomib and Dexamethasone is
significant; when the PKA and PKC activity level is high enough
with large doses of db-cAMP and Prostratin, which are required
for a higher reactivation rate, the contribution of the potentiating
effect of Bortezomib and Dexamethasone becomes minimal.
When Bortezomib concentration is high, it could inhibit the
downstream molecules of PKA and PKC pathways [42]. This is
consistent with our observation that when there are large amounts
of db-cAMP and Prostratin, increasing Bortezomib has an
inhibitory effect.
On the other hand, the data provides several questions that can
be the basis for new studies. The results suggest that a strong
positive interaction exists between Valproate and Prostratin. The
underlying mechanisms of this interaction are not clear and
require further investigation. Moreover, it is of importance to
investigate further the causes of positive or negative interactions of
the signals inducing reactivation. The utilization of the proper
interactions, by judicious selection of drug doses, led to a
significant increase in virus reactivation. Furthermore, there are
indications of accelerated response with a combination of signals
as opposed to a single signal. This potential acceleration in the
response suggests the nonlinearity of the cellular responses. It
provides multiple opportunities to verify, analyze, and quantify this
change, particularly for providing a mathematical framework for
this change, as well as for studying some of its mechanistic causes.
Materials and Methods
Selection of drugs for KSHV reactivation
In our previous work, a genome-wide cDNA screen was
performed to systematically identify cellular signals that regulate
viral reactivation [19]. Combined with existing literature, a list of
signals that reactivate KSHV was identified. In this study, five
drugs were selected to investigate the effect of multiple signals on
the reactivation of KSHV. The five drugs are: Bortezomib, db-
cAMP, Prostratin, Valproate, and Dexamethasone. Each of the
five drugs was shown to reactivate the virus from latency to
different extents.
Bortezomib is a proteasome inhibitor that at least in part
reactivates KSHV by inhibiting NF-kB activity [13]. Dibutyr-
ylcAMP (db-cAMP) is a cell-permeable cAMP analog that
activates the PKA pathway [14]. Prostratin activates the PKC
pathway [13]. Valproate shares structure and mechanism
similarities with the histone deacetylase inhibitor butyrate [15].
Dexamethasone is a glucocorticoid regulating the activation of
some transcription factors and apoptosis-related genes [16,17].
With the utilization of the five drugs that function in different
yet potentially connected signaling processes (Figure 1A), KSHV
reactivation can serve as an excellent model system illustrating
how multiple cellular signals are processed. One additional
objective is maximizing reactivation through the proper selection
of signal combinations. The interactions in the figure are an
oversimplified set of interactions of the drugs used. The simplified
diagram serves to illustrate some of the known interactions within
the cell upon treatment with various drugs. The drugs are also
known to affect other targets in addition to the intended target
enzymes and as such can lead to unknown interactions. Moreover,
each pathway has various interactions with more pathways that
are not depicted. Furthermore, upon treatment with multiple
stimuli, only a subset of these interactions will play the main role in
the response. Hence, it is important to identify this subset as it can
shed light into the inner workings of the cellular machinery in the
presence of multiple signals. The study represents an initial effort
to address the challenges of such complex interactions.
Cell preparation and measurements
The BC-3-G cell line was established as previously described
[9]. Briefly, the parental cell line BC-3 is latently infected with
KSHV. The BC-3-G cell line was established by cotransfecting
pPAN-122-d2EGFP (a construct expressing enhanced EGFP
driven by activation of PAN promoter) and a construct containing
a puromycin-resistant gene. The selected cell colonies were
maintained in RPMI 1640 medium containing 15% FBS and
puromycin, and periodic check of GFP inducibility was per-
formed. The KSHV reactivation level was indicated by the
percentage of GFP+ve cells in the total cell population as
measured on a Becton Dickinson FACScan Analytic Flow
Cytometer.
In our setup, the cells were plated in 24-well plates (5|105
cells/well). The next day a series of drug solutions were freshly
made either by diluting the stocks with media (all drugs except
valproate) or from dry powder (valproate) as manufacturers
suggested, so that 1006 solutions were available for desired
concentrations for each drug. The cells were treated with drug
combinations by adding individual 1006 drug solutions into the
well and mixing by pipetting up and down. The cells were then
returned to the incubator for 1 hour. Afterwards the cells were
washed and incubated for an additional 16 hours in fresh media to
allow enough time for the viral responses to the drug treatment to
be converted to quantitative GFP expression. Then the GFP
measurements by FACS were taken. The FACS acquisition and
analysis settings were validated by including the same positive
(TPA-treated cells) and negative (DMSO-treated cells) controls for
each set of experiments.
The western blots were performed using a rabbit polyclonal
antibody against KSHV early lytic protein K8, and the
quantification of the western blot bands was done using the
Image-Quant image analysis software (Molecular Dynamics).
The RT-Q-PCR was performed in an Opticon2MJ thermocycler
(MJ Research).The primers used for RT-Q-PCRwere: ORF50-F (5-
CACAAAAATGGCGCAAGATGA-3) and ORF50-R (5- TGGT-
AGAGTTGGGCCTTCAGTT-3); PAN-F (5-GCCGCTTCT-
GGTTTTCATTG-3) and PAN-R (5-TTGCCAAAAGCGAC-
GCA-3); GAPDH-F (5-GAAGGTGAAGGTCGGAGTC- 3) and
GAPDH-R (5-GAAGATGGTGATGGGATTTC-3).
Measurement of virion production. Supernatants from
cells treated with chemicals were collected and cleared by
centrifugation first at 200 | g for 3 min, followed by another
centrifugation at 3000 | g for 5 min. Cleared supernatants were
then treated with DNase I (Invitrogen) at a concentration of
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30 min in the presence of 10 mM of EDTA, supernatants were
treated with proteinase K (Sigma-Aldrich) at 650C for 2 hrs.
Virion DNA was extracted with phenol/chloroform, followed by
DNA precipitation with ethanol. DNA was air-dried, dissolved in
40 ml of TE buffer, and measured with RT-Q-PCR using primers
specific for the KSHV major capsid gene.
Neural network model
A multi-layered perceptron with two hidden layers was used to
fit the model. The hidden layers consisted of 40 and 20 neurons
respectively. The transfer function (activation function) of each
neuron is a sigmoidal function. The selection of this neural
network structure was a result of trying different structures with a
varying number of neurons. The input and output data was pre-
processed prior to training by mapping them into the [21, 1]
range. Outputs of the network were post-processed to map them
back to the original range. Preprocessing of data allows for better
training of the network. A back-propagation Levenberg-Mar-
quardt algorithm was used to train the neural network. The neural
network fitting algorithm divides the data into three sets, training
(98%), validation (1%), and testing (1%). The training and
validation sets are used to train the model and prevent overfitting
of data. The testing data is used for post analysis to assess the
models predictive capabilities. However, this set is small and no
meaningful conclusions can be drawn from it. Instead, we tested
an additional set of 48 combinations and used that to test the
generalizability of the model (see main text). The low percentages
of validation and training set sizes were chosen to maximize the
number of points used to fit the model. Training of the model was
done using the neural network toolbox of Matlab.
Cross entropy description and setup
We applied the cross entropy combinatorial optimization
algorithm both to the predictive reactivation model and
experimentally to optimize multi-drug combinations for high
KSHV reactivation. The search process evolves in iterations in
which the performances of selected points are evaluated. The
selected points are randomly chosen using joint Gaussian
probability density function over the set of all combinations. The
assumption of independence between the different input variables
results in a joint density function which is the product of Gaussian
distributions, each associated with an input variable. Each
Gaussian distribution has a mean and a standard deviation which
are continuously updated through the iterations of the algorithm.
The means and standard deviations of the distributions reflect the
current belief of the values of the maximizing inputs as well as the
confidence level. The evolution of the means and standard
deviations is based on the convex combination of the current
means and standard deviations, and the means and standard
deviations of a top performing percentage of model-predicted (or
experimentally-measured) performances. The algorithm termi-
nates when the change in the means becomes small and the
standard deviations approach zero.
In the experimental CE implementation, and similar to the
simulated CE implementation, 45 drug combinations were
selected in our setup to enable the collection of as many stimuli-
response data as enabled by manual measurements. In each
iteration, the performances of 45 randomly chosen sample
combinations were experimentally evaluated. The top performing
16% of combinations were used to update the means and standard
deviations. The choice of 45 combinations was based on a feasible
number of combinations to be tested manually in duplicates and
based on the previous section. The iterations proceeded for
months.
The response of the virus is experimentally measured and is
denoted by the function
y~J KSHV(u),
where u~(u1,u2,u3,u4,u5), with uj corresponding to the concen-
trations of drug j. Therefore, for any vector v~(v1,v2,v3,v4,v5),
J KSHV(v) denotes the KSHV reactivation rate as measured
experimentally with the drug concentrations being v1,v2,v3,v4,v5.
Because of the large range of concentrations used, the input range
was mapped to the log2 range, i.e., the range of each input is
~ u umin
j ~log2 umin
j ,
~ u umax
j ~log2 umax
j :
Notice that since the smallest value for the concentrations is
zero, taking the log is not possible. Instead, we replace the zero
elements in the concentrations with a pseudo element equal to one
half of the lowest concentration greater than zero. Whenever the
random outcome of a sample element is the pseudo element, it is
replaced with zero in the testing stage.
Therefore, the elements of the samples, i.e., vj,i, j~1,...,N,N~
45 and i~1,...,5, can be randomly generated using independent
probability density functions fi(:,½^ m mi,^ s si ). The parameters ^ m mi and ^ s si
are estimated in every iterations using the cross entropy method (see
the supplemental methods section for more information). The initial
value of the vector ^ h h~(^ m m1,^ s s1,^ m m2,^ s s2,^ m m3,^ s s3,^ m m4,^ s s4,^ m m5,^ s s5) was set to
^ h h~({26:0754,6:0553,{11:4658,6:0553,{18:1096,6:0553,{11:
8808,6:0553,{25:7535,6:0553). The choice for the initial values of
the means was based on picking a point in the middle of the possible
range of concentrations. The choice for the standard deviation was
made large enough to have the initial random outcomes span the
space properly.
To make sure that all data points lie within the allowable input
range, any point lying outside the allowable input range was
dropped and a new point was generated using the same
probability density function. Furthermore, the random outcomes
are rounded off or discretized to the nearest possible concentration
value in the following manner. First, let ~ v vc
j,i be a randomly
generated element in the log2 range. Locate the two concentra-
tions directly smaller and directly larger than the randomly
generated concentration; denote these points by p1 and p2
respectively. The discretized value in the log2 range is
~ v vd
j,i~
p1, ~ v vc
j,i
1
2(p1zp2);
p2, ~ v vc
j,i§(p1zp2):
(
The discretizedlog2 concentration,~ v vd
j,i,isconverted tothenormal
range using vj,i~2~ v vd
j,i. A smoothing update of both ^ m mj and ^ s sj was
also used as indicated in the supplements methods. The smoothing
parameter values were a~0:9,b~0:03 and m~0:8. Moreover, the
elite sample fraction was set to r~0:16, i.e., the top performing
seven samples are used to generate the new parameter ^ h h.
It is important to note that implementation of the CE method to
the mathematical model is not necessary unless the number of
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method provides a computational faster approach for searching for
the optimal. For systems with 5 drugs a simple sorting algorithm
that ranks combinations based on their performance suffices and is
reasonably fast.
Linear regression and variable selection
We used a regression model that is linear in the log of the
concentrations. The model is of the form
Y~b0zX1b1zX2b2z...zXnbn~XB,
where Y is the output of the model (reactivation rate), bi are the
coefficients of the model, and Xi are the regressors. A total of 31
regressors were used, the regressors correspond to the individual
concentrations, and products of concentrations for two, three,
four, and five-drug mixtures. The product terms reflect interac-
tions between the drugs. All regressors were standardized to zero
mean and unit variance.
Examining the eigenvalues of the correlation matrix X0X,
multicollinearity was checked and the model exhibited multi-
collinearity, i.e., the regressors are not linearly independent.
Therefore, a smaller number of regressors can be used without loss
of prediction. To reduce the dimensionality, we utilize different
approaches. Partial least squares was used in one approach,
however, interpretation of the reduced variables is not easy given
the large number of variables used. The second method we used
was all-subset regression. Here an efficient branch-and-bound
algorithm is used to sort through 231{1 models and to determine
the best models of 1,2,...,31 variables [38]. Selection of the
number of variables that best describe the data is based on finding
the smallest model that results in 95% reduction in the residual
sum of squares.
Evaluation of the convergence of the cross entropy
method
To evaluate the convergence of the cross entropy method, we
ran several simulations. First, one thousand different runs of cross
entropy were executed, each using 45 samples per iteration. The
same initial means and standard deviations were used for all one
thousand runs. The results showed that the algorithm converged
to combinations whose performance is within 16% of the
maximum performance. Out of the one thousand runs, 556
converged within 5% of the maximum performance and 778
within 10% of maximum performance. A similar set of simulations
was also conducted except that the initial means for the one
thousand runs were randomly chosen, thereby starting with
different parts of the combination space. All one thousand runs
converged within 21% of the maximum. 557 runs converged to
within 5% of the maximum performance, whereas 776 converged
within 10% of the maximum performance.
A similar set of simulations was also conducted in which the
number of samples per iterations was increased to 100 samples,
thereby sampling the combination space with a higher density.
The results show that with all runs starting from the same initial set
of means and standard deviations, all runs converged to
combinations with a performance within 13% of the maximum
performance. Out of the one thousand runs 730 converged within
5% and 922 within 10%. Starting with randomly chosen means at
the beginning of every run resulted in similar numbers with all one
thousand runs converging within 13% of the maximum perfor-
mance, with 735 runs converging within 5% and 935 converging
within 10%.
In the above simulations, the algorithm used the performances
of the top performing 16% of the samples within each iteration to
update the means and standard deviations. Decreasing the
number to 8% with 100 samples per iteration the algorithm
converged within 12% of the maximum performance for all one
thousand runs starting with the same initial set of means and
standard deviations. 850 converged within 5% and 987 converged
within 10%. Starting from randomly chosen means convergence
was to within 16% of the maximum performance with 859 runs
converging within 5% and 984 runs within 10%.
In all, the simulations suggest that the optimization algorithm is
capable of consistently identifying top performing combinations
without requiring to test many samples. This also introduces an
important question on whether the algorithm can be utilized to
drive a set of experimental trials to optimize the reactivation of the
virus reactivation. Such a result would provide validation of the
computational approach and would also suggest a direct
experimental approach that can be used to optimize drug
combinations through a sequence of trials.
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